Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics
| Autor: | David Back, Patrick G. Hoggard, Stefano Bonora, Helen Reynolds, Riccardo Raiteri, Alessandro Sinicco, Isabella Arnaudo, Marta Boffito, Giovanni Di Perri, Antonio Di Garbo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2002 |
| Předmět: |
Male
Immunology Lopinavir/ritonavir Salvage therapy HIV Infections Pyrimidinones Pharmacology Lopinavir Pharmacokinetics HIV Protease immune system diseases medicine Immunology and Allergy Humans Protease inhibitor (pharmacology) Salvage Therapy Ritonavir business.industry virus diseases HIV Protease Inhibitors Viral Load CD4 Lymphocyte Count Infectious Diseases Treatment Outcome Mutation HIV-1 Female Viral disease business Viral load medicine.drug |
| Popis: | Lopinavir/ritonavir was administered to 35 HIV-infected patients after therapeutic failure with other protease inhibitors. The pharmacokinetics (trough concentrations) and baseline viral genotype were determined, together with the immunovirological outcome. The 22 responders had significantly higher mean lopinavir concentrations and lower baseline numbers of mutations. On multivariate analysis, a lopinavir concentration of 5.7 microg/ml or greater was an independent predictor of viral suppression over a 9-month follow-up period. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|